These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 15683599)

  • 1. Rationale for combination therapy with statin drugs in the treatment of dyslipidemia.
    Ansell BJ
    Curr Atheroscler Rep; 2005 Feb; 7(1):29-33. PubMed ID: 15683599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of combination therapy for dyslipidemia: a lipid clinic approach.
    Brown AS
    Am J Cardiol; 2002 Nov; 90(10B):44K-49K. PubMed ID: 12467939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination therapy for combined dyslipidemia.
    Xydakis AM; Ballantyne CM
    Am J Cardiol; 2002 Nov; 90(10B):21K-29K. PubMed ID: 12467937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination therapy for dyslipidemia: safety and regulatory considerations.
    Davidson MH
    Am J Cardiol; 2002 Nov; 90(10B):50K-60K. PubMed ID: 12467940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of dyslipidemia: how and when to combine lipid lowering drugs].
    Schulz I
    Arq Bras Endocrinol Metabol; 2006 Apr; 50(2):344-59. PubMed ID: 16767301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Drug combination therapies for patients with hyperlipidemia and its significance].
    Onuma T; Kawamori R
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():566-71. PubMed ID: 11347133
    [No Abstract]   [Full Text] [Related]  

  • 7. Is there evidence-based hypolipidemic treatment with clinical benefit beyond statins?
    Goumas GS
    Angiology; 2009; 60(1):93-8. PubMed ID: 19019838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review of trials evaluating nonstatin lipid-lowering therapies.
    Ansell BJ
    Curr Atheroscler Rep; 2009 Jan; 11(1):64-6. PubMed ID: 19080730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale, design features, and baseline characteristics: The Heart Institute of Japan-PRoper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ-PROPER).
    Kawada-Watanabe E; Ogawa H; Koyanagi R; Arashi H; Yamaguchi J; Matsui K; Hagiwara N
    J Cardiol; 2017 Mar; 69(3):536-541. PubMed ID: 27349705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LDL reduction: how low should we go and is it safe?
    Robinson JG
    Curr Cardiol Rep; 2008 Nov; 10(6):481-7. PubMed ID: 18950559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Ezetimibe with statins].
    Jublanc C; Giral P; Turpin G
    Presse Med; 2006 Mar; 35(3 Pt 2):487-94. PubMed ID: 16550148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statins, fibrates, nicotinic acid, cholesterol absorption inhibitors, anion-exchange resins, omega-3 fatty acids: which drugs for which patients?
    Drexel H
    Fundam Clin Pharmacol; 2009 Dec; 23(6):687-92. PubMed ID: 19682084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Niacin as a component of combination therapy for dyslipidemia.
    Miller M
    Mayo Clin Proc; 2003 Jun; 78(6):735-42. PubMed ID: 12934785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal lipid modification: the rationale for combination therapy.
    Backes JM; Gibson CA; Howard PA
    Vasc Health Risk Manag; 2005; 1(4):317-31. PubMed ID: 17315604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
    Tenenbaum A; Fisman EZ; Motro M; Adler Y
    Adv Cardiol; 2008; 45():127-153. PubMed ID: 18230960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Should we treat all primary prevention patients with statins?
    Guthrie R
    Curr Atheroscler Rep; 2009 Jan; 11(1):36-42. PubMed ID: 19080726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LDL = 5: Virtues and dangers of multidrug therapy of low-density lipoprotein cholesterol.
    Phillips W; Schaefer S
    Prev Cardiol; 2010; 13(2):69-71. PubMed ID: 20377808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety.
    Hou R; Goldberg AC
    Endocrinol Metab Clin North Am; 2009 Mar; 38(1):79-97. PubMed ID: 19217513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic implications of recent ATP III guidelines and the important role of combination therapy in total dyslipidemia management.
    Boden WE
    Curr Opin Cardiol; 2003 Jul; 18(4):278-85. PubMed ID: 12858126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Therapy of dyslipidemia in post-infarction: state of the art].
    Borgia MC; Nardi M; Da Ros S; Castellano V
    Clin Ter; 2007; 158(6):523-32. PubMed ID: 18265719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.